Earned Wealth Advisors LLC Grows Holdings in Eli Lilly and Company $LLY

Earned Wealth Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 13.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,632 shares of the company’s stock after purchasing an additional 434 shares during the period. Earned Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $3,341,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Commonwealth Financial Services LLC lifted its stake in shares of Eli Lilly and Company by 1.2% during the first quarter. Commonwealth Financial Services LLC now owns 1,049 shares of the company’s stock valued at $965,000 after buying an additional 12 shares during the period. Carson Advisory Inc. boosted its position in Eli Lilly and Company by 6.3% during the first quarter. Carson Advisory Inc. now owns 781 shares of the company’s stock worth $718,000 after acquiring an additional 46 shares during the last quarter. Meeder Asset Management Inc. grew its stake in Eli Lilly and Company by 5.9% in the 1st quarter. Meeder Asset Management Inc. now owns 29,919 shares of the company’s stock worth $27,519,000 after acquiring an additional 1,672 shares during the period. Meeder Advisory Services Inc. grew its stake in Eli Lilly and Company by 0.4% in the 1st quarter. Meeder Advisory Services Inc. now owns 19,473 shares of the company’s stock worth $17,910,000 after acquiring an additional 76 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Eli Lilly and Company by 3.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,895,925 shares of the company’s stock valued at $3,582,704,000 after acquiring an additional 124,352 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s acquisition of AtaiBeckley adds late-stage psychedelic assets, including BPL-003, and broadens its neuroscience pipeline. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
• Positive Sentiment: Analysts and market commentary say the deal reinforces Big Pharma’s interest in psychedelic therapies and could strengthen Lilly’s long-term growth story beyond obesity and diabetes. AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies
• Neutral Sentiment: Lilly also announced an update on an ongoing ALS study, indicating continued clinical development activity across its broader pipeline. Lilly Expands ALS Pipeline With Long-Term Safety Study for LY4256984
• Neutral Sentiment: LLY stock is being described as holding near a buy zone and key support ahead of second-quarter results, suggesting investors are also watching upcoming earnings for confirmation of the growth outlook. Eli Lilly Stock Hovers In Buy Zone, Finds Key Support Amid $3 Billion Deal
• Negative Sentiment: Some market commentary suggests the acquisition may pressure sentiment in the near term because Lilly is paying a significant price for an asset that still carries clinical and regulatory risk. This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks

Eli Lilly and Company Trading Down 0.1%

Shares of LLY opened at $1,178.01 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $1.11 trillion, a P/E ratio of 41.85, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51. The stock’s fifty day simple moving average is $1,118.87 and its 200 day simple moving average is $1,036.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 34.55 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on LLY shares. Guggenheim increased their price target on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 15th. UBS Group upped their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Leerink Partners increased their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Finally, JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.